S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$27.89
+0.49 (+1.79%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$27.50
$28.24
50-Day Range
$26.86
$36.95
52-Week Range
$19.35
$38.20
Volume
342,175 shs
Average Volume
403,692 shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.13

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.09 Rating Score
Upside/​Downside
65.4% Upside
$46.13 Price Target
Short Interest
Bearish
8.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.81mentions of Xencor in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$739,628 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.80) to ($2.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

295th out of 996 stocks

Pharmaceutical Preparations Industry

132nd out of 484 stocks


XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Xencor Full Year 2022 Earnings: EPS Beats Expectations
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Why Shares of Zencor Rose This Week
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
Xencor Earnings Preview
Xencor Inc
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
2/23/2023
Today
4/01/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.13
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+65.4%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
10 Analysts

Profitability

Net Income
$-55,180,000.00
Pretax Margin
-33.12%

Debt

Sales & Book Value

Annual Sales
$164.58 million
Book Value
$12.14 per share

Miscellaneous

Free Float
57,491,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
0.82

Key Executives

  • Bassil I. DahiyatBassil I. Dahiyat
    President, Chief Executive Officer & Director
  • John J. Kuch
    Chief Financial Officer & Senior Vice President
  • John R. Desjarlais
    Chief Scientific Officer & Senior VP-Research
  • Allen YangAllen Yang
    Chief Medical Officer & Senior Vice President
  • Celia Eckert
    Secretary, Senior Vice President & General Counsel













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

10 Wall Street research analysts have issued 12-month target prices for Xencor's shares. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's stock price to reach $46.13 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2023?

Xencor's stock was trading at $26.04 at the beginning of 2023. Since then, XNCR shares have increased by 7.1% and is now trading at $27.89.
View the best growth stocks for 2023 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its earnings results on Thursday, February, 23rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.63. The biopharmaceutical company earned $21.61 million during the quarter, compared to the consensus estimate of $19.24 million. Xencor had a negative trailing twelve-month return on equity of 7.47% and a negative net margin of 33.53%. The business's revenue was down 86.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.21 EPS.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $27.89.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 4/2/2023 by MarketBeat.com Staff